S. Murray Sherman to Receptors, Vascular Endothelial Growth Factor
This is a "connection" page, showing publications S. Murray Sherman has written about Receptors, Vascular Endothelial Growth Factor.
Connection Strength
0.050
-
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study. Thyroid. 2024 03; 34(3):347-359.
Score: 0.050